ライフサイエンスコーパス: we treated

1 We treated 1-month-old PD mice with an AAV2.9-MCK-TFEB vector

2 We treated 10 childhood ALL patient-derived xenograft models

3 n in determining the main features of SIV infection in SMs, we treated 12 SMs with a potent antiretroviral therapy (ART)

4 Patients and Methods We treated 22 patients with advanced-stage lymphoma in a clin

5 We treated 3 patients with Ph(+) ALL with autologous or allog

6 Between April 19, 2012, and Nov 12, 2014, we treated 47 patients with FOLFIRINOX alone (n=8) or with FO

7 Results We treated 49 patients in phase I and 44 patients in phase II

8 of peripheral huTNF-alpha in the observed brain phenotype, we treated 5XFAD/Tg197 mice systemically with infliximab, an

9 We treated 6 human immunodeficiency virus/HCV coinfected kidn

10 We treated 7 patients with B-cell acute lymphoblastic leukemi

11 We treated a dilated cardiomyopathy-linked mouse model expres

12 Therefore, we treated a mouse model of AD, the 5xFAD model, with two dos

13 We treated a series of 4 patients with GPP with ustekinumab,

14 We treated AAV-TBG-Cre; Rosa(YFP) mice with diethylnitrosamin

15 te the clinical application of targeting JAK for ALK- ALCL, we treated ALK- cell lines of various histological origins wi

16 We treated asphaltenes from North and South American crude oi

17 In the context of population science, we treated clinical trials as small, scientifically rigid pop

18 We treated db/db mice with a selective SGLT2 inhibitor JNJ 39

19 We treated DBA/2J mice for 28 days with paroxetine and assess

20 When we treated DCs with the PNVs, we found that the cell viabilit

21 We treated exposure as time-varying when it was updated annua

22 Coincident with these zebrafish findings, we treated five medically intractable Dravet syndrome patient

23 We treated groups of nude mice bearing 7-d-old SW1222 xenogra

24 We treated high anxiety-related behavior (HAB) mice with Mito

25 We treated human aortic endothelial cells with exogenous amph

26 sly established a model of premalignant lung cancer wherein we treated human bronchial epithelial cells (HBEC) with low d

27 We treated human umbilical vein endothelial cells (HUVECs) wi

28 sease in conditions of pathological NK-cell overactivation, we treated irradiated Ldlr(-/-) mice reconstituted with eithe

29 osure of this critical period for leptin-stimulated growth, we treated Lep(ob/ob) mice with exogenous leptin during a var

30 We treated mice bearing WEHI-164 fibrosarcoma with a combinat

31 anti-inflammatory drugs can modulate the ductular response, we treated mice suffering from a steatotic or cholestatic inj

32 Here, we treated mice with daily intranasal administration of insul

33 We treated mice with either adeno-associated viruses encoding

34 tic intervention in rapidly progressive glomerulonephritis, we treated mice with established glomerulonephritis with nutl

35 To study DNA repair, we treated mice with the DSB repair inhibitor NU7441.

36 To examine the role of MARCKS in the PKC pathway, we treated MKs with polymethacrylate (PMA), which markedly in

37 ether SHP2 alters autoimmunity and related immunopathology, we treated MRL/lpr mice with an SHP2 inhibitor and found incr

38 To test the hypothesis, we treated murine atrial HL1 cardiomyocytes with increasing d

39 We treated our patient with ustekinumab, an antibody that bin

40 Taking advantage of the NR selectivity, we treated partially oxidized graphene sheets (po-Gr) with NR

41 We treated plasmid pWH1266, which contains ampicillin resista

42 ine the effectiveness of PR3 as a potential therapy for RP, we treated Rho(P23H) mice with PR3 and assessed retinal struc

43 In this study, for the first time, we treated SIV-infected sooty mangabeys, a natural host for t

44 To test this hypothesis, we treated SKO mice with the hypoglycemic sodium-glucose cotr

45 Further, we treated THP-1 monocytes and monocytes sorted from healthy

46 In this paradigm, we treated timed-pregnant mice with polyinosinic:polycytidyli

47 In this study, we treated Trex1(-/-) mice with RTIs.

48 To unravel the mechanism of action of ketamine, we treated wild-type C57BL/6 mice with calcium/calmodulin-dep

49 n with phaeohyphomycosis due to Alternaria alternata, which we treated with topical antifungal medication.

50 We treated WT mice with a single intraspinal injection of eit